查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405889

癌症免疫疗法市场规模、份额和趋势分析报告：2024-2030 年按产品、应用、分布、最终用途、地区和细分市场进行的预测

Cancer Immunotherapy Market Size, Share & Trends Analysis Report, By Product, By Application, By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

癌症免疫治疗市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球癌症免疫治疗市场规模将达2,243亿美元，2024年至2030年复合年增长率为8.3%。

其有针对性的行动导致免疫疗法的采用率超过其他癌症治疗方法，预计在预测期内采用率还会增加。此外，独裁机构对肿瘤学新型免疫疗法越来越多的监管核准也有望进一步推动市场成长。例如，2021年10月，美国FDA核准基因泰克公司的TECENTRIQ（Atezolizumab ）用于治疗NSCLC。

此外，癌症免疫疗法药物强大的产品平臺是市场强劲成长的关键驱动力之一。例如，它是由Astra Zeneca开发的，作为小细胞肺部恶性的一线治疗（III期）。免疫肿瘤药物在提高存活率和降低毒性方面显示出有希望的结果。这些临床试验的结果预计将在未来几年增加新治疗方案的推出。

癌症治疗联合治疗的日益普及预计也将进一步推动免疫疗法的需求。联合治疗针对肿瘤微环境内的多种途径，因此有可能增强免疫疗法的疗效。公司主要致力于开发标靶治疗疗法作为治疗癌症疾病的新疗法。

免疫疗法的引入为乳腺癌、脑肿瘤、膀胱癌和淋巴瘤等恶性的治疗选择提供了支持。然而，与化疗、放射线治疗和手术相比，这种治疗方法仅使用小剂量。预计免疫疗法将在未来几年成为恶性的主要治疗策略。癌症发生率的惊人上升激发了全球对癌症药物和其他治疗方法的合作研究。例如，2020 年 3 月， Astellas Pharma 和 CytomX 合作扩大了下一代免疫肿瘤治疗药物的产品线。此次合作将有助于加强每家公司的免疫肿瘤产品组合。

此外，针对復发和难治性恶性的新型免疫疗法的市场开拓和核准正在加速癌症免疫疗法市场的扩张。例如，2022年2月，强生旗下杨森製药公司宣布美国FDA核准CARVYKTI用于治疗四线或以上疗法的难治性多发性骨髓瘤。

癌症免疫治疗市场报告亮点

  • 由于单株抗体研发投入的增加，单株抗体领域在2023年占据了最大的市场占有率。
  • 在副产品中，癌症细胞溶解病毒疗法和癌症疫苗子区隔由于其在晚期恶性患者中的临床效用，预计将增长最快。
  • 从应用来看，由于盛行率上升和免疫疗法的采用增加，肺癌在市场上占据主导地位。
  • 由于人们对前列腺癌的认识不断提高以及产品发布数量的增加，前列腺癌子区隔可能会出现最快的复合年增长率。
  • 由于医院对免疫治疗药物的需求不断增加以及癌症患者入院人数的增加，医院和诊所细分市场将在 2023 年引领市场。
  • 由于医疗保健完善且未满足的医疗需求较高，预计亚太地区在预测期内将成长最快。
  • 新兴市场的领导公司不断开拓新治疗方法并进行地理扩张，以扩大其全球市场足迹。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章癌症免疫治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 癌症免疫治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章癌症免疫治疗市场：产品评估与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的全球癌症免疫治疗市场展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 单株抗体
    • 免疫调节剂
    • 溶瘤病毒疗法和癌症疫苗

第五章癌症免疫治疗市场：应用估算与趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球癌症免疫治疗市场按应用前景展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 黑色素瘤
    • 摄护腺癌
    • 头颈癌
    • 卵巢癌
    • 胰臟癌
    • 其他的

第六章癌症免疫治疗市场：分布估计与趋势分析

  • 2023年及2030年二级市场占有率
  • 细分仪表板
  • 全球癌症免疫治疗市场分布展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 医院药房
    • 零售药房
    • 网路药房

第七章癌症免疫治疗市场：最终用途估计和趋势分析

  • 2023年及2030年二级市场占有率
  • 细分仪表板
  • 按最终用途分類的全球癌症免疫治疗市场展望
  • 2018-2030 年市场规模、预测与趋势分析如下
    • 医院/诊所
    • 癌症研究中心
    • 其他的

第八章癌症免疫治疗市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
    • 2023年主要公司市占率分析
    • Pfizer Inc.
    • AstraZeneca
    • Merck &Co., Inc
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Lilly
    • Johnson &Johnson Services, Inc
    • Immunocore, Ltd
Product Code: GVR-1-68038-693-6

Cancer Immunotherapy Market Growth & Trends:

The global cancer immunotherapy market size is expected to reach USD 224.30 billion by 2030, registering a CAGR of 8.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.

Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.

Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.

The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.

Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.

Cancer Immunotherapy Market Report Highlights:

  • Monoclonal antibodies segment held the largest market share in 2023 owing to rising investments in the R&D of monoclonal antibodies
  • By product, the oncolytic viral therapies & cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
  • Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
  • The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
  • The hospitals & clinics segment led the market in 2023 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
  • Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
  • Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Distribution
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing R&D activities by pharmaceutical companies
      • 3.2.1.3. Technological advancements and introduction of novel drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of side effects associated with the treatment
      • 3.2.2.2. High cost of therapy and unfavorable reimbursement scenario
  • 3.3. Cancer Immunotherapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cancer Immunotherapy Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Monoclonal Antibodies
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Immunomodulators
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Cancer Immunotherapy Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Lung Cancer
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Breast Cancer
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Colorectal Cancer
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Melanoma
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Prostate Cancer
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Head and Neck Cancer
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Ovarian Cancer
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Pancreatic Cancer
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

  • 6.1. Distribution Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospital Pharmacy
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Retail Pharmacy
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Online Pharmacy
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

  • 7.1. Distribution Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Cancer Immunotherapy Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals & Clinics
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Cancer Research Centers
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. Pfizer Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. AstraZeneca
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Merck & Co., Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Bristol-Myers Squibb Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Novartis AG
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Lilly
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Immunocore, Ltd
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 6 North America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 7 US Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 8 US Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 9 US Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 10 US Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 14 Canada Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 18 Europe Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 19 Europe Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Germany Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 22 Germany Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 23 Germany Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 24 UK Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 25 UK Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 27 UK Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 28 France Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 29 France Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 30 France Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 31 France Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 35 Italy Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Spain Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 37 Spain Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 38 Spain Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 39 Spain Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 41 Denmark Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 42 Denmark Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 43 Denmark Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 45 Sweden Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 46 Sweden Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 47 Sweden Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Norway Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 49 Norway Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 50 Norway Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 51 Norway Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 57 China Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 58 China Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 59 China Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 60 China Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Japan Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 62 Japan Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 63 Japan Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 64 Japan Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 65 India Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 66 India Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 67 India Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 68 India Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 69 South Korea Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 70 South Korea Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 71 South Korea Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 72 South Korea Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Australia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 74 Australia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 75 Australia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 76 Australia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Thailand Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 78 Thailand Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 79 Thailand Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 80 Thailand Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Latin America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 82 Latin America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 83 Latin America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 84 Latin America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 85 Latin America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Brazil Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 87 Brazil Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 88 Brazil Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 89 Brazil Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Mexico Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 91 Mexico Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 92 Mexico Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 93 Mexico Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 97 Argentina Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 100 MEA Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 101 MEA Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 102 MEA Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 105 South Africa Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 106 South Africa Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 113 UAE Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 114 UAE Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Cancer Immunotherapy market: market outlook
  • Fig. 14 Cancer Immunotherapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Cancer Immunotherapy market driver impact
  • Fig. 20 Cancer Immunotherapy market restraint impact
  • Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
  • Fig. 22 Cancer Immunotherapy market: Product movement analysis
  • Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
  • Fig. 24 Monoclonal Antibodies market estimates and forecast, 2018 - 2030
  • Fig. 25 Immunomodulators market estimates and forecast, 2018 - 2030
  • Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2018 - 2030
  • Fig. 27 Cancer Immunotherapy Market: Application movement Analysis
  • Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
  • Fig. 29 Lung Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 30 Breast Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 31 Colorectal Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 32 Melanoma market estimates and forecasts, 2018 - 2030
  • Fig. 33 Prostate Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 34 Head and Neck Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 35 Ovarian Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Pancreatic Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030
  • Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
  • Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
  • Fig. 40 Hospital Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 41 Retail Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 42 Online Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 43 Cancer Immunotherapy market: End Use movement analysis
  • Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
  • Fig. 45 Hospitals & Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 46 Cancer Research Centers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
  • Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
  • Fig. 50 Global Cancer Immunotherapy market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, by country
  • Fig. 62 North America
  • Fig. 63 North America market estimates and forecasts, 2018 - 2030
  • Fig. 64 U.S.
  • Fig. 65 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 66 Canada
  • Fig. 67 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 68 Europe
  • Fig. 69 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 70 UK
  • Fig. 71 UK market estimates and forecasts, 2018 - 2030
  • Fig. 72 Germany
  • Fig. 73 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 74 France
  • Fig. 75 France market estimates and forecasts, 2018 - 2030
  • Fig. 76 Italy
  • Fig. 77 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 78 Spain
  • Fig. 79 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 80 Denmark
  • Fig. 81 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 82 Sweden
  • Fig. 83 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 84 Norway
  • Fig. 85 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 86 Asia Pacific
  • Fig. 87 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 88 China
  • Fig. 89 China market estimates and forecasts, 2018 - 2030
  • Fig. 90 Japan
  • Fig. 91 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 92 India
  • Fig. 93 India market estimates and forecasts, 2018 - 2030
  • Fig. 94 Thailand
  • Fig. 95 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 96 South Korea
  • Fig. 97 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 98 Australia
  • Fig. 99 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 100 Latin America
  • Fig. 101 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 102 Brazil
  • Fig. 103 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 104 Mexico
  • Fig. 105 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 106 Argentina
  • Fig. 107 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 108 Middle East and Africa
  • Fig. 109 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 110 South Africa
  • Fig. 111 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 112 Saudi Arabia
  • Fig. 113 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 114 UAE
  • Fig. 115 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 116 Kuwait
  • Fig. 117 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 118 Market share of key market players- Cancer Immunotherapy market